CSPC PHARMA (01093): High-selectivity KAT 6 inhibitor (SYH2095 tablet) approved for clinical trials in the United States

CSPC PHARMA (01093) announced that the group's collaboration with Hangzhou Yingchuang Medical Technology Co., Ltd. to develop a new type of chemical drug, SYH2095 tablets, has been approved by the U.S. Food and Drug Administration (FDA) for clinical trials in the United States. This product is a novel high-selective lysine acetyltransferase 6 (KAT 6) inhibitor, belonging to a class of epigenetic anti-cancer drugs. The product works by inhibiting the acetylation of lysines on histones, blocking open chromatin, and regulating cell cycle, estrogen receptor expression, and cell senescence pathways, thus exerting anti-tumor effects, and is intended for use in advanced malignant tumors. Preclinical studies have shown that the product exhibits highly effective and selective inhibition of KAT 6, significantly inhibiting tumor growth, and demonstrating good pharmacokinetic properties and safety. Currently, there are no approved drugs targeting the same pathway for marketing domestically or internationally, making this product highly valuable in clinical development.